# MELISA Institute Genomics & Proteomics Research SpA: Phase 3 study withdrawn (COVID-19, SARS-CoV2)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | MELISA Institute Genomics & Proteomics Research SpA |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers |
| NCT ID | NCT04446065 |
| Phase | Phase 3 |
| Status | withdrawn |
| Conditions | COVID-19; SARS-CoV2 |
| Intervention types | drug |
| Posted | 2020-06-24 |
| Planned start | 2020-09-30 |
| Event | Withdrawn before enrolling |
| Event date | 2026-10-19 |
| Last update posted | 2026-10-19 |

## Why this score
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.
- Phase 3: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04446065). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.